# Bostal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bostal

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.bostaldrug.com
- Latest round: Series B (Aug 19, 2023)
- Investors on record: 15

## About

Based in Guangzhou, China, and founded in 2013, Guangzhou Bostao Controlled Release Pharmaceutical Co., Ltd doing business named Bostal, is a drug release system drug and pharmaceutical preparation research and development outsourcing service provider that develops, manufactures, and markets innovative drugs and generic drugs. As of August 2023,  the company employs about 400 employees. The company was established by Dr. Rong Liu and Weiqin Tong. It has two production bases in Guangzhou,  a gas pedal industrial park, and an internationalized agent industrialization base, which covered 6,800 square meters, and 68,000 square meters, respectively. In August 2023, Bostal raised series B2 funding from new investors BOC & Utrust Fund, Chuangyu Capital, Guangdong Technology Financial Group, Guangzhou Panyu Fund, Karma Capital, Knowledge City Group, Oct Capital, Wanlian Guangsheng Investment, Wanlian Tianze, Yimi Venture.

The company provides entecavir tablets used for the treatment of chronic adult hepatitis B (including patients with compensated and decompensated liver disease) with active viral replication, persistently elevated serum alanine aminotransferase (ALT), or histological evidence of active liver disease. Bostal also has a wide range of product research and development pipelines, with products covering the treatment of various major diseases, such as metabolic diseases, psychiatric disorders, malignant tumors, cardiovascular and cerebrovascular diseases, and more. The company has developed platforms of preparation technologies, including oral sustained and controlled release preparations, gastro retentive sustained-release preparation, solubilization of insoluble drugs, orodispersible films, long-acting injection implants, long-acting microsphere for injection, nano injectables, long-acting gel for injection, and liposome.

The company will use the series B2 funding for the development and production of the new drug  505(b) (2).

## Funding rounds

- Series B, Aug 19, 2023 — Guangdong Technology Financial Group, Yuecai Zhongyin Private Equity, Chuangyu Capital, Wanlian Tianze, Yimi Venture, Guangzhou Panyu Fund, Karma Capital, October Capital, Wanlian Guangsheng Investment, Knowledge City (Guangzhou) Investment Group
- Series B, Apr 19, 2022 — Huatai Zijin Investment, Sanmei Capital, Chuangyu Capital, Guangzhou Jet Biofiltration Co.,Ltd.
- Angel, Mar 20, 2017 — JIC Capital, Guangzhou Guoju Venture Capital

## Investors

- JIC Capital (https://capitalatlas.ai/funds/jic-capital) — Angel
- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Angel
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- Sanmei Capital (https://capitalatlas.ai/funds/sanmei-capital) — Series B
- Chuangyu Capital — Series B
- Guangzhou Jet Biofiltration Co.,Ltd. — Series B
- Guangdong Technology Financial Group (https://capitalatlas.ai/funds/guangdong-technology-financial-group) — Series B
- Yuecai Zhongyin Private Equity (https://capitalatlas.ai/funds/yuecai-zhongyin-private-equity) — Series B
- Wanlian Tianze (https://capitalatlas.ai/funds/wanlian-tianze) — Series B
- Yimi Venture (https://capitalatlas.ai/funds/yimi-venture) — Series B
- Guangzhou Panyu Fund (https://capitalatlas.ai/funds/guangzhou-panyu-fund) — Series B
- Karma Capital (https://capitalatlas.ai/funds/karma-capital) — Series B
- October Capital (https://capitalatlas.ai/funds/october-capital) — Series B
- Wanlian Guangsheng Investment — Series B
- Knowledge City (Guangzhou) Investment Group — Series B